An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg

Overview

cited authors

Pratley, Richard E.; Catarig, Andrei-Mircea; Lingvay, Ildiko; Viljoen, Adie; Paine, Abby; Lawson, Jack; Chubb, Barrie; Gorst-Rasmussen, Anders; Miresashvili, Nino

authors

Pratley, Richard Edwin, MD

Publication Date

August 9, 2021

webpage

Web of Science

published in

DIABETES OBESITY & METABOLISM Journal

Research

keywords

GLP-1 receptor agonist
dulaglutide
indirect comparison
semaglutide
type 2 diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.